Printer Friendly

I-FLOW CORP. RECAPS SIGNIFICANT EVENTS FOR 1992

 I-FLOW CORP. RECAPS SIGNIFICANT EVENTS FOR 1992
 IRVINE, Calif., Feb. 11 /PRNewswire/ -- I-FLOW Corp. (NASDAQ: IFLO),


manufacturer and seller of innovative ambulatory infusion technologies, reported today that in view of the apparent recent market activity in I-FLOW's common stock, significant events that have taken place so far this year should be understood.
 In January, a patent application was filed on a new disposable drug delivery system capable of providing low-cost intravenous delivery of antibiotics and other small volume drugs. This new infusion system is currently under review by the U.S. Food and Drug Administration (FDA). I-FLOW has begun discussions with several healthcare companies on a possible licensing and marketing agreement for this new product, scheduled for market introduction in July 1992.
 An order for 100 VIVUS 4000/2 infusion systems was received in February from a major home healthcare company. This order alone is expected to generate revenues equal to or slightly greater than the total revenues for calendar year 1991.
 On Feb. 10, 1992, I-FLOW completed a $2.0 million special warrant exercise financing. This warrant exercise program was offered at a reduced exercise price, for a limited time to current shareholders who held a total of 6,378,666 warrants from previous I-FLOW private placements. A total of 5,594,937 warrants were exercised in exchange for the issuance of the same number of shares of I-FLOW common stock, resulting in gross proceeds received of $1,958,228. Holders exercising these warrants also agreed with the company not to sell any of these shares for a period of 180 days. This exercise of 5,594,937 warrants by current shareholders represents 88 percent of the total warrants subject to exercise in this financing. Because of working capital requirements to support the projected growth and new product development and marketing, additional financing may be necessary later this year.
 I-FLOW currently manufactures and sells technically advanced, multiple-channel, ambulatory infusion systems uniquely well suited to the alternate care environment. Reliable, convenient, I-FLOW products offer users substantial opportunities to expand their therapy base, improve quality of care, and increase productivity. These advantages translate into improved revenues and profits for healthcare providers while reducing costs and improving the quality of life for patients.
 -0- 2/11/92
 /CONTACT: Jim Dal Porto of I-FLOW, 714-553-0888/
 (IFLO) CO: I-FLOW Corp. ST: California IN: MTC SU:


AL-CH -- LA011 -- 8795 02/11/92 12:17 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1992
Words:400
Previous Article:ERS MOVES AHEAD IN MASSACHUSETTS PERMITTING PROCESS
Next Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR FEB. 11, 1992
Topics:


Related Articles
RALPHS GROCERY CO. ANNOUNCES CONSUMMATION OF PLAN OF REORGANIZATION
I-FLOW CORPORATION LOWERS EXERCISE PRICE OF PUBLICLY HELD WARRANTS
I-FLOW CORP. RECEIVES $1.6 MILLION IN ADDITIONAL FUNDING
Fujitsu Software ships new version of iFlow workflow product.
Silicon Access Networks Delivers Revolutionary Networking Coprocessor Using 24Mb STAR Memory System From Virage Logic.
Fujitsu Software Partners with Covigna to Provide Advanced BPM Capabilities To Contract Management Offering; Covigna Is the Latest Addition to...
Siemens Demonstrates Flexibility, Enhanced Workflow and Imaging Excellence.
SIEMENS UNVEILS ENHANCED WORKFLOW/IMAGING EXCELLENCE.
BNY Mellon Introduces iFlow(SM) Enhancements; Interactive Flow Monitor (iFlow) Analytics Provide Uniquely Comprehensive, Up-to-Date Insights into...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters